401 / 1835
Conclusion
•
DIBH implementation in lymphoma very succesful
•
Protocol in lung cancer patients ongoing
•
Clear dosimetric benefit, even when using VMAT/IMRT
•
Ressource investment: the ”sore points” are
–
PET scanning time
–
IGRT
–
And even then, they remain very manageable !